The effect of heterogeneity on HIV prevention trials

Clinical Trials

Volumn 8, Issue 2, 2011, Pages 144-154

  Auvert, Bertran ^a,b   Sitta, Rémi ^a   Zarca, Kevin ^a   Mahiane, Séverin Guy ^a   Pretorius, Carel ^c,d   Lissouba, Pascale ^a  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d AVENIR HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; MICROBICIDE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CIRCUMCISION; CLINICAL TRIAL (TOPIC); CROSSOVER PROCEDURE; HERPES SIMPLEX; HETEROGENEITY EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INTERMETHOD COMPARISON; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SAMPLE SIZE; STATISTICAL ANALYSIS; UTERINE CERVIX CAP;

ADULT; AFRICA SOUTH OF THE SAHARA; AFRICAN CONTINENTAL ANCESTRY GROUP; COMPUTER SIMULATION; CROSS-OVER STUDIES; FEMALE; HETEROSEXUALITY; HIV INFECTIONS; HUMANS; INDIVIDUALITY; MALE; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK FACTORS; SEXUAL PARTNERS;

EID: 79959221683     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774511398923     Document Type: Article

References (50)

1. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357: 1149-53. (Pubitemid 32378686)
2. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2: e298.
3. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369: 657-66.
4. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369: 643-56.
5. Laga M, Alary M, Nzila N, et al. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 1994; 344: 246-48.
6. Wald A. Synergistic interactions between herpes simplex virus type-2 and human immunodeficiency virus epidemics. Herpes 2004; 11: 70-76. (Pubitemid 40064891)
7. Philpott S, Weiser B, Tarwater P, et al. CC chemokine receptor 5 genotype and susceptibility to transmission of human immunodeficiency virus type 1 in women. J Infect Dis 2003; 187: 569-75. (Pubitemid 36250020)
8. Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8: 553-63.
9. Garcia R, Benet M, Arnau C, Cobo E. Efficiency of the cross-over design: an empirical estimation. Stat Med 2004; 23: 3773-80. (Pubitemid 40074076)
10. Feingold M, Gillespie BW. Cross-over trials with censored data. Stat Med 1996; 15: 953-67. (Pubitemid 26168320)
11. Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003; 348: 2416-22. (Pubitemid 36682820)
12. Team RDC. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2005.
13. Holford TR. The analysis of rates and of survivorship using log-linear models. Biometrics 1980; 36: 299-305.
14. Auvert B, Ballard R, Campbell C, et al. HIV infection among youth in a South African mining town is associated with herpes simplex virus-2 seropositivity and sexual behaviour. AIDS 2001; 15: 885-98. (Pubitemid 32424392)
15. Auvert B, Buve A, Ferry B, et al. Ecological and individual level analysis of risk factors for HIV infection in four urban populations in sub-Saharan Africa with different levels of HIV infection. AIDS 2001; 15: S15-30.
16. Ferry B, Carael M, Buve A, et al. Comparison of key parameters of sexual behaviour in four African urban populations with different levels of HIV infection. AIDS 2001; 15: S41-50.
17. Lagarde E, Auvert B, Chege J, et al. Condom use and its association with HIV/sexually transmitted diseases in four urban communities of sub-Saharan Africa. AIDS 2001; 15: S71-78.
18. Padian NS, van der Straten A, Ramjee G, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 2007; 370: 251-61. (Pubitemid 47069513)
19. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359: 463-72.
20. Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998; 339: 504-10. (Pubitemid 28384883)
21. Richardson BA, Lavreys L, Martin Jr HL, et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis 2001; 28: 394-400. (Pubitemid 32613682)
22. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360: 971-77. (Pubitemid 35284107)
23. Kaul R, Kimani J, Nagelkerke NJ, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004; 291: 2555-62. (Pubitemid 38702773)
24. Peterson L, Nanda K, Opoku BK, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE 2007; 2: e1312.
25. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 2109-19. (Pubitemid 351902179)
26. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358: 1560-71. (Pubitemid 351519816)
27. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 2008; 3: e1474.
28. Halpern V, Ogunsola F, Obunge O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS ONE 2008; 3: e3784.
29. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1977-87.
30. Greenland S. Absence of confounding does not correspond to collapsibility of the rate ratio or rate difference. Epidemiology 1996; 7: 498-501. (Pubitemid 26277694)
31. Hernan MA. The hazards of hazard ratios. Epidemiology 2010; 21: 13-15.
32. Anderson RM, Ng TW, Boily MC, May RM. The influence of different sexual-contact patterns between age classes on the predicted demographic impact of AIDS in developing countries. Ann N Y Acad Sci 1989; 569: 240-74. (Pubitemid 20103372)
33. Rosenbaum PR. Heterogeneity and causality: unit heterogeneity and design sensitivity in observational studies. Amer Statist 2005; 59: 147-52. (Pubitemid 40622503)
34. Cane VR, Mcnamee R. The spread of infection in a heterogeneous population. J Appl Probab 1982; 19A: 173-84.
35. Becker NG. Analysis of infectious disease data. In: Chapman and Hall/CRC (ed.). Monographs on Statistics and Applied Probability. Chapman and Hall, Boca Raton, 1989, pp. 87-101.
36. Becker NG, Marschner IC. The effect of heterogeneity on the spread of disease. In: Gabriel JP, Lefevre C, Picard P. (eds). Stochastic Processes in Epidemic Theory. Springer-Verlag, New York, 1990, pp. 90-103.
37. Wilson DP. Interpreting sexually transmissible infection prevention trials by adjusting for the magnitude of exposure. Clin Trials 2010; 7: 36-43.
38. Liu W, Zhao W, Shaffer ML, et al. Modelling clinical trials in heterogeneous samples. Stat Med 2005; 24: 2765-75. (Pubitemid 41358707)
39. Gray RH. Methodologies for evaluating HIV prevention intervention (populations and epidemiologic settings). Curr Opin HIV AIDS 2009; 4: 274-78.
40. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010; 24: 621-35.
41. Lancaster T. The Econometric Analysis of Transition Data. Cambridge University Press, Cambridge, 1990.
42. Aalen OO. Heterogeneity in survival analysis. Stat Med 1988; 7: 1121-37.
43. Abbring JH, Van Den Berg GJ. The unobserved heterogeneity distribution in duration analysis. Biometrika 2007; 94: 87-99.
44. Aalen OO. Modelling heterogeneity in survival analysis by the compound Poisson distribution. Ann Appl Probab 1992; 2: 951-72.
45. Moger TA, Aalen OO, Halvorsen TO, et al. Frailty modelling of testicular cancer incidence using Scandinavian data. Biostatistics 2004; 5: 1-14. (Pubitemid 41180232)
46. Zhang B, Li Y, Betensky RA. Effects of unmeasured heterogeneity in the linear transformation model for censored data. Lifetime Data Anal 2006; 12: 191-203. (Pubitemid 44222582)
47. Betensky RA, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002; 20: 2495-99. (Pubitemid 34525735)
48. Griffin BA, Lagakos SW. Analysis of failure time data arising from studies with alternating treatment schedules. JASA 2006; 101: 510-20. (Pubitemid 43972294)
49. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-94. (Pubitemid 32378696)
50. Hallett TB, Garnett GP, Mupamberiyi Z, Gregson S. Measuring effectiveness in community randomized trials of HIV prevention. Int J Epidemiol 2008; 37: 77-87. (Pubitemid 351228617)